BioCentury
ARTICLE | Preclinical News

Inhibiting IL-22 could treat KRAS-mutant lung cancer

May 17, 2018 9:15 PM UTC

A study published in Cancer Immunology Research from scientists at the University of Texas MD Anderson Cancer Center suggests inhibiting IL-22 could help treat KRAS-mutant lung cancer.

High levels of IL-22 and IL-22-positive cells in primary lung tumors and sera from lung cancer patients have been previously reported. Additionally, patients with non-small cell lung cancer (NSCLC) had higher levels of IL-22 receptor subunit alpha 1 (IL22RA1; IL22R; IL22R1), which was associated with poor overall survival...